[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Nippon Shinyaku Co. Ltd.
Nippon Shinyaku and Capricor Therapeutics announce positive Phase X results for Deramiocel, potentially leading to FDA approval and commercialization. However, concerns remain regarding the near-term impact of the Uptravi patent cliff.
About Nippon Shinyaku Co. Ltd.
Nippon Shinyaku Co. Ltd. is a pharmaceutical company.
Insights
- Nippon Shinyaku Co. Ltd. creators is up XXX% from the previous week.
- Nippon Shinyaku Co. Ltd. mentions is up XXXXXX% from the previous week.
- Nippon Shinyaku Co. Ltd. Price hit a 52-Week high of $XXXXX for the hour
- Nippon Shinyaku Co. Ltd. Price hit an all time of $XXXXX for the hour
Price: $
Price 24-Hour Time-Series Raw Data
The recent price surge is likely driven by positive developments in the RGX-121 partnership with Capricor Therapeutics, overshadowing concerns related to the Uptravi patent cliff, as indicated by social media discussions and analyst ratings.
1-Year High: $XXXXX on 2025-12-09
1-Year Low: $XXXXX on 2025-07-14
AltRank: XXX
AltRank 24-Hour Time-Series Raw Data
Nippon Shinyaku Co. Ltd. is currently AltRank #999 based on combined combined social and market metrics
Daily Average: XXX
1-Year High: XXXXX on 2024-12-13
1-Year Low: XXX on 2025-01-15
Galaxy Score: XX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1-Year High: XX on 2025-01-14
1-Year Low: XX on 2025-01-11
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXXXX -XX%
X Month: XXXXXX +6,235%
X Months: XXXXXX -XX%
X Year: XXXXXXX -XXXX%
1-Year High: XXXXXX on 2025-01-14
1-Year Low: X on 2025-04-24
Engagements by network (24h): X: XXX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: XX +167%
X Month: XX no change
X Months: XXX -XX%
X Year: XXX +73%
1-Year High: XX on 2025-02-06
1-Year Low: X on 2024-12-18
Mentions by network (24h): X: XX
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning Nippon Shinyaku Co. Ltd. in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: XX +150%
X Month: XX -XX%
X Months: XX -XX%
X Year: XXX +55%
1-Year High: XX on 2025-02-06
1-Year Low: X on 2024-12-18
The most influential creators that mention Nippon Shinyaku Co. Ltd. in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @avidresearch | X | XXXXXX | X | XXX |
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Month: XXX% no change
X Months: XXX% +33%
X Year: XXX% no change
1-Year High: XXX% on 2024-12-29
1-Year Low: XX% on 2025-09-18
Most Supportive Themes:
- Capricor Therapeutics Partnership: (70%) Nippon Shinyaku's collaboration with Capricor Therapeutics on the drug RGX-121 is generating significant positive attention, with multiple posts highlighting the potential value and clinical success of this collaboration.
- Stock Performance and Valuation: (20%) Discussions around Nippon Shinyaku's stock performance, including recent price surges and comparisons to its market cap relative to its drug revenue share with Capricor, are prominent.
Most Critical Themes:
- Patent Cliff Concerns: (10%) The Morgan Stanley downgrade due to the Uptravi patent cliff is a significant concern, potentially impacting future revenue streams and market position.
Market Cap: $undefined
Market Cap 24-Hour Time-Series Raw Data
Current Value: $undefined
Daily Average: $XXXXXXXXXXXXXXX
1-Year High: $XXXXXXXXXXXXXXX on 2024-12-17
1-Year Low: $XXXXXXXXXXXXXXX on 2025-02-03
Top Nippon Shinyaku Co. Ltd. Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$WVE definitely has X INHBE valuation built into it. 👇 Would argue its exon XX drug should justify most of its current valuation. They will be submitting WVE-N531 NDA to FDA next year. Vyondys XX from $SRPT and Viltepso from Nippon Shinyaku are X drugs approved for exon XX DMD. Both collectively bring in about $250M-$300M/yr (Viltepso brought in $70.8M in H1 2025). There are no other late stage players. $WVE drug is vastly superior to both of these approved drugs (just look at dystrophin levels) and will be monthly dosing option(vs weekly for X approved drugs)"
X Link @avidresearch 2025-12-08T11:27Z 11.7K followers, 9945 engagements
"Nippon Shinyaku and Capricor announce positive Phase X results for Deramiocel with potential FDA approval and commercialization on the horizon. Near term concerns with Viltepso remain"
X Link @Generic_Tina 2025-12-08T00:35Z XX followers, XX engagements
"$TSE Nippon Shinyaku Co. Ltd. (TSE:4516) Stock Catapults XX% Though Its Price And Business Still Lag The Market - #stocks #news"
X Link @StockTickerZone 2025-12-05T07:40Z 3959 followers, XXX engagements
"Here's Capricor's $CAPR current valuation and cash burn. They have XXX years of cash left so could hold off on a capital raise for a bit if they want to and they are definitely undervalued based on peak sales expectations $1b even if they split profits with Nippon Shinyaku"
X Link @biotech_hunter 2025-12-04T18:37Z XXX followers, 1477 engagements